HistoRx Inc., a cancer therapy diagnostics firm based in New Haven, won a $1.5 million loan from Connecticut’s quasi-public life sciences initiative.
HistoRx is developing what it calls AQUA, technology designed to assess the potential effectiveness of cancer drugs and predict patients’ responses to the treatments. The system uses fluorescence-based image analysis and automated microscopy to measure protein molecules. Connecticut Innovations, the quasi-public equivalent of the Mass. Life Sciences Center, is loaning the company $1.5 million to build out laboratory space and buy equipment.